MigVax Ltd.


MigVax was established in 2020, as MIGAL’s subsidiary.
MigVax Ltd., has been developing MigVax-101, an oral subunit COVID-19 vaccine, based on a successful vaccine for chickens developed by MIGAL for Infectious Bronchitis Virus (IBV), a poultry Coronavirus.
MIGAL is an internationally-recognized multi-disciplinary applied research institute established in 1979 in Israel’s Northern Galilee, is addressing the world’s most pressing challenges by research in agriculture, food, feed, health and environment. Based on extensive work in developing an oral subunit vaccine for IBV, an avian (poultry) coronavirus, MIGAL designed a flexible vaccine design system that can be adapted rapidly to virus mutations.